Strong growth even if it’s still losing money.
5 Likes
Revenue grew organically slightly less than last quarter, but on the other hand, the gross margin improved. Still, one can’t be disappointed with that growth 
Edit: Oh, apparently, we can be disappointed 
-23%
1 Like
CELLINK has entered into an agreement to acquire Nanoscribe, a market leading 3D bioprinting company based on Two-Photon Polymerization technology
4 Likes
6 Likes
CELLINK has acquired Visikol, a contract research services company focused on advanced imaging, 3D cell culture assays and digital pathology
7 Likes
I have to ask this now as I can’t find anything myself (my Swedish is very poor, and reading, for example, Avanza through a translator didn’t clarify the situation at all):
It’s been coming down pretty fast for a couple of days. Is there any information why?
1 Like
Could this be the reason? The Nanoscribe news is old, but the details of the payment in shares are in this May 31st publication.
2 Likes
Thanks! The timing is spot on, so I guess the culprit has been found.
1 Like
New purchase
6 Likes
The quarterly report day (August 18) is approaching, and Swedish small investors tend to buy heavily before such an event. The company is also enjoying a tailwind (at least ostensibly) with its acquisitions. Some companies’ prices drop sharply even after good results…
Could it be that there’s a subgroup that collects the cream off the cake before moving on to the next one?
1 Like
Since there are so few messages in the thread, I’ll answer here as well.
In addition, Monday’s launch announcement may have generated some buzz. They are also looking into the possibility of a name change.
1 Like
For some, it might create a bit of extra buzz:
https://twitter.com/mw_stocks/status/1418475968461746176?s=21
7 Likes
Yes, the TP was raised to SEK 600.
3 Likes
Today, the results for early 2021 were announced. The stock price before the stock markets opened was 554 SEK (YTD +136% and +236% in a year).
Cellink has just changed its name to BICO Group Ab.
BICO Group AB: Interim report January-June 2021: Increased net sales of 628% driven by M&A and organic growth of 95% and positive EBITDA in Q2.
7 Likes
7 Likes
I’ve been on board for just under a year and have added to my position three times. This week I was still considering adding more, but I think I missed the boat. I’m curious to see what happens to the share price after an earnings release like this. Will this be the rocket in my portfolio?
3 Likes
About BICO
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people’s health and lives for the better. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health. The Group’s products are trusted by more than 2,000 laboratories, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,850 publications. BICO is listed on the Nasdaq Stockholm under BICO.
“ In five years, we have built a world-leading group that offers something truly unique – a bio convergence revolution ”, said Erik Gatenholm, CEO and President BICO. “A s the company has continued to grow, we saw limitations to make radical change in the industry and at our customers’ laboratories with just one product. We realized that our customers needed more and better technologies, products, solutions, and to create the most change. I am proud to introduce BICO to the world and look forward to continuing to push the boundaries of science to create the future of health. ”
1 Like
Shopping again
4 Likes
BICO announces intention to carry out a directed issue of approximately SEK two billion
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, HONG KONG, NEW ZEALAND, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE CONTRAVENING TO ANY APPLICABLE RULES. ADDITIONAL RESTRICTIONS ARE APPLICABLE, PLEASE SEE “IMPORTANT INFORMATION” IN THE END OF THIS PRESS RELEASE.
BICO announces intention to carry out a directed issue of approximately SEK two billion
1 Like
Through the Share Issue, the Company’s share capital will increase by SEK 106,250.00 from SEK 1,442,685.43 to SEK 1,548,935.43, by new issue of 4,250,000 series B shares, resulting in the total number of shares increasing from 57,707,417 shares to 61,957,417 shares together carrying in total 75,457,417 votes, whereof 1,500,000 are series A shares together carrying 15,000,000 votes and 60,457,417 are series B shares together carrying 60,457,417 votes. The Share Issue results in a dilution of approximately 7 percent of the capital and approximately 6 percent of the votes for existing shareholders based on the total number of shares and votes in the Company after the Share Issue.
Members of the Board of Directors and the management team, of which several are large shareholders in BICO, have entered into lock-up agreements to, subject to certain exceptions, not sell shares in BICO for a period of 90 calendar days after the settlement date. Furthermore, the Company has agreed to a commitment, with customary exceptions, not to carry out any additional share issuances for a period of 90 calendar days after the settlement date.
2 Likes